Our results, together with the compelling evidence from animal models, argue that TGF-β antagonists offer great therapeutic potential for restoring anti-tumour immunity and suggest that the effects of these agents on the human immune system warrants careful evaluation. The gene discussed is TGFB1; the disease is neoplasm.